MARKET

GNMK

GNMK

GenMark
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.79
+0.29
+2.15%
After Hours: 13.79 0 0.00% 16:42 12/03 EST
OPEN
13.59
PREV CLOSE
13.50
HIGH
14.09
LOW
13.53
VOLUME
323.81K
TURNOVER
--
52 WEEK HIGH
20.88
52 WEEK LOW
3.360
MARKET CAP
989.03M
P/E (TTM)
-33.9739
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Genmark Diagnost Falls 2.92% on Heavy Volume: Watch For Potential Rebound
Genmark Diagnost (NASDAQ:GNMK) traded in a range yesterday that spanned from a low of $12.25 to a high of $12.75. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $12.49 on volume of 381,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Comtex SmarTrend(R) · 11/25 18:05
GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum
GenMark Diagnostics, Inc. (NASDAQ: GNMK) ("GenMark" or the "Company"), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTech & Diagnostics Forum.
GlobeNewswire · 11/05 21:11
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
GenMark Diagnostics EPS beats by $0.01, beats on revenue
GenMark Diagnostics (GNMK): Q3 GAAP EPS of -$0.05 beats by $0.01.Revenue of $42.65M (+103.9% Y/Y) beats by $2.96M.Press Release
Seekingalpha · 10/28 20:19
GenMark Diagnostics Reports Third Quarter 2020 Results
GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2020.
GlobeNewswire · 10/28 20:15
GenMark Diagnostics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 28, 2020 / GenMark Diagnostics, Inc. (NASDAQ: GNMK) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on October 28, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 10/28 18:31
APTX, GNMK, HXL and RAIL among after-hours movers
Gainers: [[APTX]] +89.3%. [[EMKR]] +14.8%. [[GNMK]] +8.9%. [[CCK]] +6.5%. [[NOK]] +3.8%.Losers: [[RAIL]] -9.6%. [[HXL]] -8.8%. [[BLU]] -6.9%. [[STLD]] -3.4%. [[TEO]] -3.3%.
Seekingalpha · 10/19 21:38
GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020
GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, October 28, 2020. Management will hold a conference call to review the company's financial performance starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.
GlobeNewswire · 10/14 21:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNMK. Analyze the recent business situations of GenMark through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNMK stock price target is 20.60 with a high estimate of 23.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 218
Institutional Holdings: 71.78M
% Owned: 100.08%
Shares Outstanding: 71.72M
TypeInstitutionsShares
Increased
51
6.75M
New
52
1.45M
Decreased
58
7.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.29%
Healthcare Equipment & Supplies
-1.15%
Key Executives
Chairman/Independent Director
Kevin O'Boyle
President/Chief Executive Officer/Director
Scott Mendel
Chief Financial Officer
Johnny Ek
Senior Vice President/General Counsel/Secretary
Eric Stier
Senior Vice President
Michael Gleeson
Senior Vice President/Director of Sales
Michael Harkins
Senior Vice President
Tyler Jensen
Independent Director
Daryl Faulkner
Independent Director
Lisa Giles
Senior Vice President
Brian Mitchell
Senior Vice President
Scott O'Brien
Independent Director
Michael Kagnoff
Vice President/Director of Human Resources
Hollis Winkler
Non-Executive Independent Director
James Fox
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GNMK
GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of GenMark Diagnostics, Inc stock information, including NASDAQ:GNMK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNMK stock methods without spending real money on the virtual paper trading platform.